Oncology
Oncology
BioLegacy provides a comprehensive suite of in vivo oncology platforms designed to deliver definitive efficacy and mechanism-of-action data for your program. Our portfolio of cancer models spans from xenografts and syngeneic tumor models representing the major type of cancers. Orthotopic implantations that faithfully replicate the unique microenvironments of diseases are available. By leveraging sophisticated models and integrating them with advanced imaging and biomarker analysis, we empower our partners with the critical, translationally relevant insights needed to accelerate their most promising candidates toward the clinic.
- Diverse Xenograft Models: Subcutaneous and orthotopic implantation of cell line-derived (CDX) and patient-derived (PDX) tumor models.
- Diverse Xenograft Models Evaluation of therapies against hematological malignancies.
- Metastasis Modeling: Advanced spontaneous and induced metastasis models to assess the efficacy of compounds against tumor invasion and colonization.
- Immuno-Oncology Platforms: A full suite of syngeneic models and humanized mice to evaluate the efficacy of checkpoint inhibitors, CAR-T cells, and other immunomodulatory agents.
- Combination Therapy Studies: Expertise in designing and executing complex study protocols to evaluate the synergistic or additive effects of combination regimens.
- Advanced In Vivo Imaging: Multi-modal imaging capabilities for therapeutic responses.
- Integrated Biomarker Analysis: In-house flow cytometry, IHC, and multiplex assay capabilities to analyze pharmacodynamic markers of target engagement and immune cell infiltration in tumor tissues.
Immunology & Inflammation
Immunology & Inflammation
BioLegacy provides an extensive portfolio of in vivo platforms to definitively assess the efficacy of your novel immunomodulatory therapeutics. Our expertise spans a wide range of inflammatory conditions, from systemic and organ-specific inflammation to validated models of arthritis, asthma, COPD, and hypersensitivity. By integrating these robust models with advanced immune cell profiling and biomarker analysis, we deliver the critical, mechanistic data you need to demonstrate target engagement and de-risk your path to IND and beyond.
- Arthritis & Joint Inflammation: Gold-standard models such as collagen-induced arthritis (CIA) with clinical, histological, and biomarker endpoints.
- Respiratory Inflammation: Validated models of allergic asthma and COPD. Readouts include airway hyperresponsiveness and BAL fluid analysis.
- Neuroinflammation: Models of chronic CNS inflammation, such as experimental autoimmune encephalomyelitis (EAE).
- Dermatology & Skin Inflammation: Robust models of psoriasis (imiquimod-induced) and atopic dermatitis to evaluate topical and systemic therapeutics.
- Gastrointestinal & Liver Inflammation
- Systemic Inflammation & Hypersensitivity: Models of systemic inflammation, sepsis (LPS, CLP), and delayed-type hypersensitivity (DTH).
- Advanced Immune Cell Profiling: In-house flow cytometry for detailed immunophenotyping of immune cell populations.
- Multiplex Cytokine & Chemokine Analysis: Meso Scale Discovery (MSD) platform to quantify key inflammatory mediators in plasma and tissue.
- Integrated Histopathology: On-site pathology services for expert scoring of inflammation, tissue damage, and therapeutic effect.
Neurology / CNS
Neurology / CNS
BioLegacy offers preclinical neurology studies leveraging a wide-ranging suite of in vivo neuroscience platforms designed to deliver definitive efficacy and mechanistic data. Our validated models span neurodegenerative disorders and multiple sclerosis to complex spinal cord injury surgeries and models of seizure and epilepsy. Armed with a battery of sensitive behavioral and cognitive tests, we provide the translatable data needed to demonstrate therapeutic potential.
- Neurodegenerative Disease Models: Validated models for Alzheimer's, Parkinson’s, and Huntington’s.
- Multiple Sclerosis & Neuroinflammation: Gold-standard experimental autoimmune encephalomyelitis (EAE) models in both mice and rats to evaluate immunomodulatory and neuroprotective agents.
- Epilepsy & Seizure Models: Validated acute and chronic seizure models to assess anti-epileptic drug efficacy.
- Comprehensive Behavioral & Cognitive Battery: A full suite of tests to assess motor function, cognition, memory, and psychiatric-like behaviors.
- Specialized CNS Dosing: Proficiency in targeted delivery routes including intrathecal (IT), intracerebral, and intranasal administration.
- Integrated CNS Biomarker Analysis: Sensitive, in-house quantification of key neurotransmitters, inflammatory cytokines, and protein aggregates in plasma and CNS tissue.
- GLP-Compliant Neuropathology: On-site pathology for quantitative analysis of neuronal loss, demyelination, and target engagement.
Cardiovascular
Cardiovascular
BioLegacy’s cardiovascular studies utilize a broad range of in vivo platforms. These include models of heart failure with preserved or reduced ejection fraction (HFpEF, HFrEF), advanced models of thrombosis and vascular remodeling, and specialized vein graft and vascular access studies. Combined with sophisticated assessments of cardiovascular function, vascular permeability, and blood flow, BioLegacy delivers the critical efficacy and mechanistic data required to gain a comprehensive understanding of your therapeutic candidates and advance your leads to regulatory submission.
- Advanced Heart Failure Models: Both HFpEF and HFrEF.
- Comprehensive Cardiovascular Function Assessment: Hemodynamic evaluation using pressure-volume (PV) loop analysis, echocardiography, and implantable telemetry.
- Thrombosis & Vascular Remodeling: Validated models of arterial and venous thrombosis and vascular injury.
- Vascular & Vein Graft: Microsurgeries for creating arteriovenous (AV) fistulas and vein graft models to study neointimal hyperplasia and graft patency.
- Blood Flow & Permeability Measurement: Precisely quantification of tissue perfusion, blood flow, and changes in vascular permeability.
- Histopathology & Biomarker Analysis: State-of-the-art on-site pathology and bioanalytical capabilities.
- Atherosclerosis Models: Evaluation of lipid-lowering and anti-inflammatory therapeutics.
Dermatology & Wound Healing
Dermatology & Wound Healing
BioLegacy’s suite of in vivo dermatology platforms deliver definitive data on your compound’s efficacy and mechanism of action. We offer quantitative models of incisional and excisional wound healing, well-characterized models of atopic dermatitis, psoriasis, and acute skin irritation, and more. In combination with specialized functional assessments, including passive cutaneous anaphylaxis assays and quantitative histopathology, we provide translationally relevant data to advance your topical or systemic therapeutic.
- Wound Healing Models: Full-thickness excisional and incisional wound models with quantitative endpoints including wound closure rates, re-epithelialization, and tensile strength.
- Inflammatory Skin Disease Models: Gold-standard psoriasis and atopic dermatitis models.
- Acute Irritation & Sensitization: Acute dermal irritation, as well as delayed-type and immediate hypersensitivity responses.
- All Relevant Administration Routes: Topical, subcutaneous, transdermal, oral, parenteral, etc.
- Advanced Bioanalytics: In-house capabilities to precisely quantify drug concentration in plasma, skin, and other tissues and biofluids.
- Quantitative Histopathology & IHC: Expert pathological interpretation and quantitative analysis of epidermal thickness, immune cell infiltration, collagen deposition, and key protein markers.
- Functional Dermal Assessments to assess skin barrier function.
- Fibrosis & Scarring Models to evaluate the efficacy of anti-fibrotic agents and therapies aimed at reducing scar formation.
Metabolism
Metabolism
Definitive data on glucose homeostasis, body composition, and lipid metabolism is essential for advancing novel therapeutics targeting metabolic disease. We generate this critical information using a comprehensive suite of well-characterized genetic and diet-induced rodent models of Type 1 and Type 2 diabetes, obesity, and hyperlipidemia. Combined with gold-standard functional assessments and key biomarker analysis, BioLegacy delivers a clear, quantitative profile of your compound’s efficacy and mechanism of action.
- Diabetes Models: Genetic and induced models for both Type 1 and Type 2 diabetes studies.
- Obesity & Hyperlipidemia Models: to assess therapeutics targeting weight loss and lipid modulation.
- Gold-Standard Functional Testing: Including glucose and insulin tolerance tests (GTT, ITT) and hyperinsulinemic-euglycemic clamps.
- Biomarker & Hormone Analysis: In-house quantification of key analytes such as insulin, glucagon, leptin, adiponectin, and comprehensive lipid panels.
Gastroenterology
Gastroenterology
A clear understanding of a compound’s effect on gut inflammation, barrier integrity, and GI function is pivotal for developing novel gastroenterology therapeutics. BioLegacy provides this critical data using extensively validated in vivo models. Our portfolio of models ranges from gold-standard chemically-induced colitis models for inflammatory bowel disease (IBD) to assessments of gastric irritation and gastrointestinal motility, delivering a definitive profile of your compound’s efficacy and / or GI-related safety.
- Inflammatory Bowel Disease (IBD) Models: Robust, chemically-induced colitis models.
- Gastrointestinal Motility Assessment: Measure gastric emptying and whole-gut transit time, providing key functional data for pro-kinetic agents or safety assessments.
- Intestinal Permeability & Barrier Function: In vivo assays using fluorescent tracers (e.g., FITC-dextran) to quantitatively assess gut barrier integrity and therapeutic restoration.
- Gastric & Intestinal Irritation Models: Evaluation of the potential for drug-induced gastric and intestinal irritation or ulceration.
- Integrated Histopathology: On-site pathology services for expert comprehensive clinical scoring of mucosal damage, inflammatory cell infiltration, and crypt architecture.
- Myeloperoxidase (MPO) Activity Assays: Measurement of neutrophil infiltration into GI tissues as a key inflammatory biomarker.
- Multiplex Cytokine Analysis: In-house bioanalytical measurement of key inflammatory mediators in both tissue homogenates and plasma.
Hepatology
Hepatology
From complex hepatobiliary surgery to comprehensive functional assessment, BioLegacy provides an integrated platform for advancing your hepatology pipeline. Our expertise includes the maintenance of a dedicated bile duct cannulated (BDC) colony for critical PK/ADME studies and proficiency in direct organ cell inoculation for advanced disease modeling and cell therapy evaluation. We leverage these specialized capabilities alongside gold-standard models of liver fibrosis and inflammation to provide a clear assessment of therapeutic efficacy, backed by robust liver function testing and quantitative histopathology.
- Liver Fibrosis & MASH Models: Robust, diet- and chemically-induced models.
- Acute & Drug-Induced Liver Injury (DILI): Validated models to assess hepatotoxicity and evaluate hepatoprotective agents.
- Bile Duct Cannulated (BDC) Models: On-site BDC rodent colony for studies of biliary excretion, enterohepatic circulation, and compound metabolism.
- Specialized Surgical Capabilities: Proficiency in complex hepatobiliary surgeries, including partial hepatectomy and direct-to-liver cell or compound inoculation.
- Comprehensive Liver Function Testing: In-house clinical chemistry analysis of key liver enzymes (ALT, AST), bilirubin, and albumin for a complete functional profile.
- Advanced Histopathology: Quantitative scoring of steatosis, inflammation, ballooning, and fibrosis.
- Hydroxyproline & Triglyceride Analysis: Biochemical quantification of liver collagen content and triglyceride levels.
- Gene Expression Analysis: In-house qPCR capabilities to measure expression of key fibrotic and inflammatory genes within liver tissue.
Pulmonology
Pulmonology
BioLegacy delivers a definitive understanding of airway hyperresponsiveness, inflammation, and fibrotic remodeling using well-characterized in vivo models for asthma, COPD, and lung fibrosis. By integrating these robust platforms with specialized dosing techniques and gold-standard functional and cellular analyses, we deliver a clear, quantitative profile of efficacy and mechanism of action for your novel respiratory therapeutics.
- Asthma Models: Acute and chronic models of allergic asthma with comprehensive readouts including airway hyperresponsiveness (AHR).
- COPD Models: Validated models which recapitulate key features of COPD, including chronic inflammation and emphysema.
- Idiopathic Pulmonary Fibrosis (IPF) Models: Gold-standard bleomycin-induced lung fibrosis models with quantitative histopathology and hydroxyproline analysis.
- Specialized Dosing Routes: Proficiency in intratracheal (IT), intranasal (IN), and nose-only inhalation administration for targeted pulmonary delivery.
- Bronchoalveolar Lavage (BAL) Fluid Analysis: In-depth cellular and biomarker analysis of BAL fluid, including differential cell counts and multiplex cytokine profiling.
- Integrated Histopathology: On-site pathology for quantitative scoring of inflammation, mucus production, and collagen deposition.
Infectious Diseases & Sepsis
Infectious Diseases & Sepsis
Tackling the dual challenges of drug-resistant pathogens and dysregulated host immunity requires preclinical models that can simultaneously assess both antimicrobial efficacy and the resulting immune response. BioLegacy’s infectious disease platform is engineered to meet this need, providing definitive data from our robust models of sepsis and drug-resistant bacterial infections. By integrating bacterial load quantification with in-depth immunophenotyping and cytokine analysis, we deliver a clear, comprehensive profile of your therapeutic’s ability to combat infection and beneficially modulate the host immune response.
- Sepsis & Systemic Inflammation Models: Expertise in gold-standard models with survival, cytokine storm, and organ dysfunction endpoints.
- Drug-Resistant Bacterial Infection Models: Validated in vivo models for testing therapeutics against ESKAPE pathogens.
- BSL-2 Containment Facility: State-of-the-art, access-controlled BSL-2 vivarium for safely conducting studies with moderate-risk pathogens.
- Specialized Infection Models: Platforms including pneumonia and wound infection models to evaluate therapeutics in clinically relevant contexts.
- Host Immune Response Profiling: In-depth analysis of systemic and local immune responses through multiplex cytokine analysis and flow cytometry.
- PK/PD Studies: to optimize dosing regimens.
- Combination Therapy Evaluation: BioLegacy can design and execute complex studies to assess the synergistic effects of novel anti-infectives with standard-of-care antibiotics.
Musculoskeletal
Musculoskeletal
A definitive evaluation of therapeutics and devices for bone safety and therapeutic potential requires a multidimensional approach, integrating functional and histological endpoints. BioLegacy provides such comprehensive assessments, leveraging our deep expertise in models of bone healing and remodeling to deliver clear definitive data. Combining robust surgical models with biomechanical testing and histomorphometry, we and our partner laboratories provide a complete profile of your therapeutic or device’s impact on tissue regeneration and structural integrity.
- Bone Healing & Fracture Models: Evaluate osteogenic agents with critical-sized defect and stabilized fracture models in both rodent and large animal species.
- Biomechanical Testing: Determine structural properties such as bone strength and stiffness with tests including torsional and three-point bending.
- Histomorphometry: Determination of bone formation rate, cartilage integrity, and inflammatory cell infiltration.
- Large Animal Models: Highly translatable ovine and porcine models for the evaluation of orthopedic devices and implants.
- Integrated Biomarker Analysis: Quantification of key markers of bone formation and resorption.
Nephrology & Urology
Nephrology & Urology
BioLegacy provides definitive data on renoprotective therapeutics using a suite of well-characterized in vivo models of kidney fibrosis, unilateral ureteral obstruction (UUO), acute renal failure, chronic kidney disease (CKD), and others. By integrating gold-standard functional assessments with in-depth biomarker analysis and quantitative histopathology, we deliver a robust profile of your small molecules, biologics, and ATMPs ability to preserve renal function and mitigate tissue damage.
- Chronic Kidney Disease (CKD) Models: Validated surgical models of progressive kidney disease to assess long-term therapeutic efficacy.
- Unilateral Ureteral Obstruction (UUO) Model: Well-established and reproducible in vivo surgical model used to study renal fibrosis and chronic kidney disease (CKD) progression.
- Renal Function Measurement: In vivo measurement of glomerular filtration rate (GFR) using FITC-inulin clearance with routine analysis of blood urea nitrogen (BUN) and serum creatinine.
- Comprehensive Urinalysis: In-depth analysis of urine for key markers of kidney damage, including albuminuria, proteinuria, and kidney injury molecule-1 (KIM-1).
- Quantitative Renal Histopathology: Expert pathological scoring of glomerulosclerosis, tubular injury, interstitial fibrosis, etc.
- Integrated Bioanalytical Support: Quantification of drug concentration in plasma and kidney tissue, correlating exposure with renoprotective effects.
